This report was first published by Endpoints News. To see the original version, click here
Biotech venture capitalists are embracing risk again, signaling a reversal from the past few years.
VCs are placing more bets on flashy new biotech opportunities in the first quarter of 2026. About 65% of investments by a group of the most active private biotech investors went into new portfolio companies, according to a quarterly report from bankers at William Blair.
您已阅读9%（459字），剩余91%（4936字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。